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Abstract
Background: Multiple myeloma is an incurable plasma cell malignancy that is mostly restricted to the bone
marrow. Cancer-induced dysfunction of cytotoxic T cells at the tumor site may be responsible for immune evasion
and therapeutical failure of immunotherapies. Therefore, enhanced knowledge about the actual status of T cells in
myeloma bone marrow is urgently needed. Here, we assessed the expression of inhibitory molecules PD-1, CTLA-4,
2B4, CD160, senescence marker CD57, and CD28 on T cells of naive and treated myeloma patients in the bone
marrow and peripheral blood and collected data on T cell subset distribution in both compartments. In addition, T
cell function concerning proliferation and expression of T-bet, IL-2, IFNγ, and CD107a was investigated after in vitro
stimulation by CD3/CD28. Finally, data was compared to healthy, age-matched donor T cells from both
compartments.
Methods: Multicolor flow cytometry was utilized for the analyses of surface molecules, intracellular staining of
cytokines was also performed by flow cytometry, and proliferation was assessed by 3H-thymidine incorporation.
Statistical analyses were performed utilizing unpaired T test and Mann-Whitney U test.
Results: We observed enhanced T cell exhaustion and senescence especially at the tumor site. CD8+ T cells
expressed several molecules associated with T cell exhaustion (PD-1, CTLA-4, 2B4, CD160) and T cell senescence
(CD57, lack of CD28). This phenotype was associated with lower proliferative capacity and impaired function.
Despite a high expression of the transcription factor T-bet, CD8+ T cells from the tumor site failed to produce IFNγ
after CD3/CD28 in vitro restimulation and displayed a reduced ability to degranulate in response to T cell stimuli.
Notably, the percentage of senescent CD57+CD28− CD8+ T cells was significantly lower in treated myeloma
patients when compared to untreated patients.
Conclusions: T cells from the bone marrow of myeloma patients were more severely impaired than peripheral T
cells. While our data suggest that terminally differentiated cells are preferentially deleted by therapy, immune-
checkpoint molecules were still present on T cells supporting the potential of checkpoint inhibitors to reactivate T
cells in myeloma patients in combination therapies. However, additional avenues to restore anti-myeloma T cell
responses are urgently needed.
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Background
Treatment of cancer aims at the deletion of all malig-
nant cells. Besides minimizing the bulk of tumor cells by
conventional therapy, the cytotoxic ability of activated T
cells is central to tumor eradication and cancer cure. T
cell anergy, exhaustion, and/or senescence are character-
ized by elevated levels of multiple inhibitory molecules,
impaired effector cytokine production, loss of proliferative
capacity, impaired cytotoxicity, and altered use of key
transcription factors including T-bet (reviewed in [1–3]).
T cell exhaustion occurs after chronic antigenic exposure
and prevents optimal control of tumors. Modulation of
molecules and pathways overexpressed in the exhaustion
phase could reverse this dysfunctional state and reinvigor-
ate immune response [4, 5]. Senescent T cells are late dif-
ferentiated memory/effector T cells which lack CD28 and
gain CD57 and regulatory receptor expression. They
rather express CD45RA than CD45RO, are in cell-cycle
arrest, and have enhanced secretion of inflammatory cyto-
kines [6]. Most studied inhibitory molecules which func-
tion as negative regulators of lymphocyte activation are
PD-1 (CD279) and CTLA-4 (CD152). Natural killer cell
receptor 2B4 (CD244), glycoprotein CD160, TIM3, Lag3,
and many others have also been shown to contribute es-
sentially to the regulation of T cell activity [2, 7]. Blocking
immune checkpoint molecules achieved promising results
in the treatment of solid cancers; however, targeting these
molecules in hematologic malignancies is relatively under-
studied [8–10]. First promising results with an anti-PD-1
antibody in the treatment of refractory Hodgkin’s lymph-
oma were recently published [11–13], and studies are
under way to investigate the effectiveness of combinations
with low-dose glucocorticoids. Recently, data on immune
checkpoints such as PD-1 expression of myeloma patients
have been published. In addition, the potential of PD-1
blocking antibodies to reactivate diseased T cells were in-
vestigated in vitro and proved this molecule as promising
candidate for immunotherapy [14–16]. In vivo, however,
these PD-1 inhibitors appear to work only in combination
with immunomodulatory drugs in myeloma patients, and
first positive results have been presented at the ASH 2015
meeting by J. San Miguel and A.Z. Badros.
Multiple myeloma is a hematologic cancer characterized
by the accumulation of malignant plasma cells within the
bone marrow. Despite the advances in therapy by the intro-
duction of novel immunomodulatory agents and prote-
asome inhibitors, this cancer remains largely incurable. The
immunogenic nature of multiple myeloma is underlined by
the observation of disease remission after allogeneic stem
cell transplantation or donor lymphocyte infusion, possibly
caused by graft-versus-myeloma effects [17, 18]. Delineating
the tumor-driven defects of the immune system in mye-
loma in more depth will contribute to the development of
novel immuno-therapeutical strategies.
Defects in T cell distribution and function have been
consistently documented in this disease, including a re-
duction of peripheral blood CD4 and CD8 T cells, inver-
sion of the CD4/CD8 ratio, abnormal Th1/Th2 ratio,
downregulation of signal transduction components, and
abnormal T cell responses [19–22]. Intriguingly, the ma-
jority of studies so far focused on immunological alter-
ations in the peripheral blood of myeloma patients
despite the fact that myeloma cells almost exclusively
grow and spread within the bone marrow. So far, little is
known regarding the composition and activity of the im-
mune system in myeloma bone marrow. In this study,
we investigated the expression of inhibitory molecules
on effector T cells as well as their function in response
to in vitro stimulation by antibodies against CD3/CD28.
We studied both T cells from peripheral blood and from
the bone marrow of myeloma patients and healthy, age-
matched donors in order to elucidate systemic and local
tumor-mediated alterations.
We demonstrate that, especially at the tumor site, both
T cell exhaustion and T cell senescence might play an
important role in supporting tumor growth. Moreover,
we show data on the T cell composition in refractory pa-




Blood samples and bone marrow aspirates from the pos-
terior iliac crest from the same patient were obtained
from 16 newly diagnosed patients (MM naive) and 6 pa-
tients treated with immunomodulatory drugs and dexa-
methasone (MM Tx) at the Department of Internal
Medicine, University Hospital of Innsbruck, Austria.
Peripheral blood samples and bone marrow aspirates
from the proximal femur of the same individuals were
taken from age-matched healthy donors in the course of
hip arthroplasty at the Department of Orthopedic Sur-
gery, University Hospital of Innsbruck (n = 12). Accord-
ing to a recent publication, T cell subset distribution is
comparable between samples from the posterior iliac
crest and proximal femur [23]. Healthy subjects were
screened for the presence of viral infections and any
bone marrow abnormalities and did not receive immu-
nomodulatory drugs or suffer from diseases known to
influence the immune system, including autoimmune
diseases or cancer.
Cell isolation from human PB and BM aspirates
Peripheral blood mononuclear cells (PBMC) and bone
marrow mononuclear cells (BMMC) were separated by
density gradient centrifugation (GE Healthcare Life Sci-
ences) and either used immediately (for flow cytometric
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analyses) or cryopreserved for later functional analysis.
Recovery rates from frozen T cells were above 85 %.
Immunofluorescence staining and flow cytometric
analysis
Staining of surface antigens was performed in erythrocyte-
free samples (blood samples and bone marrow aspirates)
by multicolour staining using fluorescently labeled CD3
(clone UCHT1), CD4 (RPA-T4), CD8 (RPA-T8), CD28
(CD28.2), CD45 (2D1), CD45RA (HI100), CD57 (NK-1),
CD62L (DREG-56), CD152/CTLA-4 (BNI3), CD160
(BY55), CD244/2B4 (2-69), CD279/PD1 (MI-H4) (all from
BD, Heidelberg, Germany). For staining of intracellular
proteins, PBMC and BMMC were stimulated with anti-
CD3 (2 μg/ml) and anti-CD28 (5 μg/ml) (both from
eBioscience/Affymetrix) for 6 or 24 h. Ten micrograms
per milliliter Brefeldin A (Sigma-Aldrich) were added to
the cell cultures for the last 4 h of incubation. Intracellular
staining was carried out using CytoFix/CytoPerm kit, ac-
cording to manufacturer’s instructions (BD). All antibodies
against cytokines (IL-2, clone 5344.111; IFNγ, B27), T-bet
(O4-46), and CD107a (H4A3) were purchased from BD.
Flow cytometry was performed on a BD FACS Canto II
flow cytometer with subsequent analysis using FACS
DIVA Software 7.0. The analysis was performed after gat-
ing on single viable cells after 7-AAD staining.
T cell proliferation and degranulation
Cell proliferation was measured by culturing BMMC at
a density of 2 × 106/ml in RPMI1640/10 % FCS together
with anti-CD3 (2 μg/ml) and anti-CD28 (5 μg/ml) anti-
bodies. 3H-thymidine (Hartmann Analytic) was added
for the last 16 h of stimulation, cells were harvested, and
3H-thymidine incorporation was measured on a ß-coun-
ter (Beckman Coulter, USA). The proliferation index was
calculated as ratio of stimulated T cells and unstimulated
controls. For assessment of degranulation, cells were
stimulated with anti-CD3 and anti-CD28 as above with
the addition of 10 μg/ml anti-CD107a antibody for 6 h
at 37 °C. For assessment of CD8+ T cell activation/pro-
liferation, 5 × 106 cells/ml (BMMC) were washed and
stained with 0.4 μM carboxyfluorescein succinimidyl
ester (CFSE; eBioscience/Affymetrix) for 5 min at room
temperature in the dark. After quenching with FCS and
washing with RPMI1640 and once with PBS, the cells
were diluted at 2 × 106/ml in RPMI1640/10 % FCS and
stimulated with anti-CD3 and anti-CD28 antibodies for
72 h as described above.
Statistical analysis
For all data sets which could be accurately modeled by a
Gaussian distribution an unpaired t test was used for ana-
lysis of differences between groups; otherwise, the Mann-
Whitney U test was used. P values of less than 0.05 were
considered statistically significant (significance levels
*p < 0.05, **p < 0.01, ***p < 0.001, n.s. not significant).
Results
Increased expression of PD-1, CTLA-4, CD160, and 2B4 on
CD8+ T cells from the bone marrow of myeloma patients
We assessed expression of inhibitory molecules on T
cells from the bone marrow (BM) and peripheral blood
(PB) of myeloma patients and healthy, age-matched indi-
viduals by multicolour flow cytometry. Patients’ charac-
teristics are summarized in Table 1.
In brief, both, CD3+CD4+ as well as CD3+CD8+ T
cells exhibited enhanced expression of PD-1 in PB as
well as BM of myeloma patients. This is in accordance
with recently published data [15, 24]. We could also
confirm enhanced expression of CTLA-4 [25], and we
found it to be restricted to bone marrow T cells of mye-
loma patients. In general, the higher the numbers of in-
hibitory receptors which are present, the more severe T
cells are exhausted. Therefore, we analyzed the expres-
sion of two additional inhibitory molecules which are
suggested to play a role in T cell regulation, i.e., CD160
and 2B4. CD160 competes with BTLA for binding to







Number Total 16 6 12
Age Median 70 65 59
Range 67–76 62–74 55–70
Sex Male 8 3 7



























The patients were classified according to the International Myeloma Working
Group (IMWG) criteria
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herpes virus entry mediator (HVEM) and has been
shown to negatively regulate TCR-mediated signaling
[26]. Crosslinking of 2B4 on T cells decreases prolifera-
tion, and 2B4 expression is upregulated on exhausted T
cells [27, 28]. In our analyses both, CD160 and 2B4,
were significantly upregulated on bone marrow T cells of
myeloma patients suggesting that the extent of local im-
mune suppression might be even higher than estimated
from the previous investigations. The percentages of T
cells expressing the respective molecules are depicted in
Table 2.
T cell subsets are altered in myeloma bone marrow
PD-1 expression on T cells has recently been described
as novel therapeutical target in myeloma disease [15]. In
general, high levels of PD-1 expression are found on ef-
fector memory T cells [29]. In depth analyses of T cell
subset distributions in myeloma are largely missing so
far which prompted us to further analyze patients’ T
cells according to CD45RA and CD62L levels. Concomi-
tantly, we analyzed PD-1 levels on the different T cell
subsets.
Whereas percentage of CD4+ subsets did not vary signifi-
cantly between healthy and diseased peripheral blood and
bone marrow compartments, CD8+ subset distribution was
strikingly altered. Briefly, we found a significant accumula-
tion of effector T cells (Temra; CD45RA+CD62L−) and an
even more pronounced decrease of effector memory T cells
(Tem; CD45RA−CD62L−) within the CD8+ T cell pool
in the myeloma bone marrow (Table 3, Fig. 1a, b). A
trend for the increase of Temra cells as a consequence
of aging has been described [30], and we found it to be
further enhanced in myeloma patients. In addition, we
found that PD-1 expression was significantly increased
in all T cell subsets (Fig. 1c).
Bone marrow CD8+ T cells of myeloma patients show
functional defects
In the next set of experiments, we assessed the ability of
BM CD8+ T cells to proliferate in response to T cell
stimulation by anti-CD3 and anti-CD28 antibodies. Pro-
liferation of CD8+ T cells from myeloma patients was
significantly lower compared to healthy controls (Fig. 2a).
To further investigate the involved mechanisms, we
compared expression of various molecules in the above
setting. First, we analyzed the transcription factor T-bet
which plays a crucial role in T cell development, regu-
lates effector function, and is essential for the induction
of IFNγ [31]. Significantly more T-bet+ CD8+ T cells
were detected in BM samples of myeloma patients.
However, upon stimulation, healthy donor T cells upreg-
ulated T-bet whereas expression in myeloma T cells
remained the same (Fig. 2b). The high constitutive ex-
pression of T-bet is consistent with a skewing towards
CD8+ effector cell subsets as shown above. Physiologic-
ally, high T-bet expression goes along with enhanced
cytokine production [32]. According to T-bet expression,
the percentage of IFNγ-expressing cells was higher in
unstimulated samples of myeloma patients compared to
healthy donors. However, upon activation, expression
was significantly downregulated in myeloma T cells
whereas it was upregulated in healthy controls (Fig. 2c).
This finding points to an activated but exhausted CD8+
T cell population in diseased BM. Interestingly, further
in depth analyses of T-bet and IFNγ expression in T cell
subsets revealed a significant decrease in the CD45RA+












PD-1+ 44.4 (17.7–60.3) 64.5 (36.8–77.4) * 47.2 (21.6–60.2) 66.6 (48.0–74.8) *
2B4+ 30.3 (7.3–43.2) 36.1 (28.4–47.3) n.s. 33.7 (17.8–45.2) 33.4 (19.1–44.6) n.s.
CD160+ 29.4 (8.3–33.2) 30.8 (23.4–39.0) n.s. 33.1 (10.5–37.3) 30.6 (16.8–38.9) n.s.
CTLA-4+ 43.5 (29.4–56.6) 60.3 (52.2–64.4) * 48.8 (37.9–59.6) 56.7 (35.6–65.4) n.s.
CD8+ T cells
PD-1+ 60.7 (50.8–69.4) 73.0 (65.7–86.8) * 50.20 (42.0–66.7) 74.1 (57.8–81.9) *
2B4+ 42.0 (24.1–46.1) 58.5 (43.1–69.0) * 56.50 (36.7–69.6) 59.4 (49.3–70.3) n.s.
CD160+ 38.7 (22.9–49.8) 56.4 (44.4–64.8) * 44.30 (16.6–57.8) 49.4 (40.5–59.2) n.s.
CTLA-4+ 53.1 (44.9–59.6) 65.8 (61.9–67.9) ** 58.55 (43.5–64.2) 64.7 (60.6–71.8) n.s.
Flow cytometric analyses of inhibitory molecules are presented as median percentage of cells expressing the respective molecules with IQR (n = 7–12). Statistical
significance was calculated using Mann-Whitney U test
n.s. not significant
*p < 0.05; **p < 0.01
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CD45RA+/CD62L+ (Tn) 24.1 (13.2–39.10) 26.0 (14.5–36.4) n.s. 18.1 (14.0–39.8) 25.7 (14.4–42.9) n.s.
CD45RA−/CD62L+ (Tcm) 44.6 (37.2–48.2) 35.0 (19.4–52.6) n.s. 48.8 (43.3–61.3) 42.4 (31.6–60.0) n.s.
CD45RA−/CD62L− (Tem) 26.0 (22.1–32.2) 23.2 (9.2–36.3) n.s. 18.7 (13.3–21.8) 15.6 (9.8–25.9) n.s.
CD45RA+/CD62L− (Temra) 4.5 (2.4–6.2) 6.2 (2.0–16.8) n.s. 2.9 (0.9–3.9) 2.4 (0.4–7.0) n.s.
CD8+ T cells
CD45RA+/CD62L+ (Tn) 11.3 (7.6–18.4) 18.5 (10.3–24.7) n.s. 14.8 (9.2–28.2) 26.3 (15.7–53.5) n.s.
CD45RA−/CD62L+ (Tcm) 13.2 (9.8–17.1) 10.2 (7.0–15.3) n.s. 23.5 (18.6–34.5) 19.4 (12.5–36.9) n.s.
CD45RA−/CD62L− (Tem) 49.6 (40.0–66.2) 27.2 (19.8–38.9) ** 30.1 (27.1–44.0) 18.5 (11.3–32.4) *
CD45RA+/CD62L− (Temra) 18.7 (15.1–27.9) 34.5 (25.7–52.4) ** 19.0 (11.4–32.3) 20.6 (7.7–31.3) n.s.
Percentages of the various T cell subsets in PB and BM were determined by flow cytometric analyses and are presented as median percentage with IQR (n = 12–16).
Statistical significance was calculated using Mann-Whitney U test
Tn naïve T cell, Tcm central memory T cell, Tem effector memory T cell, Temra effector T cell, n.s. not significant
*p < 0.05; **p < 0.01
Fig. 1 Accumulation of an activated CD8+ T cell population in the BM of myeloma patients. a The dot plots show the gating strategy as well as the
proportion of human CD8+ T cell subsets of a representative healthy and myeloma BM sample. The numbers indicate the percentage of naive (Tn:
CD45RA+CD62L+), central-memory (Tcm: CD45RA-CD62L+), effector memory (Tem: CD45RA−CD62L−) and effector (Temra: CD45RA+CD62L−) CD8+ T
cells. b Pie charts summarize the median proportion of Tn, Tcm, Tem, and Temra in PB and BM for 12 healthy and 16 myeloma samples. c Percentages of
PD-1 expressing CD8+ T cell subsets (Tn, Tcm, Tem, and Temra) of healthy, age-matched controls and myeloma patients were assessed by flow cytometry
(n= 11; median with interquartile range (IQR) is shown). Significance levels *p< 0.05; **p< 0.01
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CD8+ T cell compartment (Tn and Temra) of myeloma
patients, whereas expression in CD45RA− CD8+ T cells
(Tcm and Tem) was similar in healthy and myeloma
people (Fig. 2d). Taking into account that effector T cells
(Temra) represent about 60 % of the T cell CD45RA+
compartment in myeloma patients, we suggest that ef-
fector cell function is markedly impaired.
Cytotoxic T cell function also relies on their functional
degranulation capacity. CD107a (LAMP1) has been de-
scribed as a marker of cytotoxic CD8+ T cell degranula-
tion and is strongly upregulated on the cell surface of this
T cell type upon stimulation [33]. Interestingly, myeloma
CD8+ T cells displayed high constitutive CD107a expres-
sion. Upon stimulation, healthy BM CD8+ T cells were
able to mobilize intracellular CD107a to the membrane
whereas degranulation of myeloma CD8+ T cells was
impaired (Fig. 2e). These data also support a decreased
cytotoxic activity of CD8+ T cells in multiple myeloma.
Together, the impaired proliferative and cytotoxic capacity
of T cells in BM of myeloma patients in response to acti-
vation suggests T cell exhaustion.
Accumulation of a senescent T cell population in
myeloma bone marrow
Under persistent antigenic stimulation, CD28 expression
is progressively and irreversibly downregulated, whereas
the expression of CD57 increases, characterizing a state of
replicative senescence [34]. Since high numbers of senes-
cent cells might additionally blunt immunotherapies, we
analyzed the extent of CD28 and CD57 expression in BM
T cells [35]. In both healthy and diseased samples, most T
cells lacked CD28 expression (Fig. 3a) whereas CD57 ex-
pression was significantly increased in myeloma bone
marrow T cells (Fig. 3b). Specifically, the total amount of
Fig. 2 CD8+ T cells of myeloma patients show functional defects in proliferation and cytotoxicity. a Proliferation was assessed by 3H-thymidine
incorporation after stimulating the cells for 72 h with anti-CD3/anti-CD28 antibodies. The proliferative index (3H-thymidine incorporation of stimulated T
cells divided by 3H incorporation of unstimulated cells) is shown for BM CD8+ T cells from myeloma patients (n= 12) and from healthy controls (n= 6).
b T-bet and c IFNγ expression was assessed by intracytoplasmic staining of total CD8+ BMMCs before (0 h) and after stimulation (24 h) of the cells (n= 7;
median with IQR is shown). d T-bet and IFNγ expression on different T cell subtypes (CD8+ CD45RA+ or CD45RA−) was assessed by intracytoplasmic
staining before (0 h) and after (24 h) stimulation with CD3/CD28 antibodies (n= 7; mean ± SEM is shown). e Surface levels of CD107a were detected by
flow cytometry before (0 h) and after stimulation (24 h) (n= 3; median with IQR is shown). Significance levels: *p < 0.05; **p< 0.01; n.s. not significant
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CD57+CD28− was significantly upregulated in myeloma
compared to healthy BM indicating the predominance of
a senescent phenotype (Fig. 3c). In addition, about 20 %
of healthy and approximately 35 % of diseased CD8+ T
cells co-expressed CD57 and PD-1. This enhanced co-
expression in myeloma suggests a distinct population of
late differentiated, senescent T cells (Fig. 3d).
Inhibitory molecules remain expressed after therapy
while CD57 is differentially expressed on CD8+ T cells in
chemo-naive and treated myeloma patients
So far, few investigations on the impact of established
therapies on the expression of inhibitory molecules or
senescence markers have been performed [15]. There-
fore, we assessed surface expression of PD-1, CTLA-4,
CD160, and 2B4, as well as expression of CD57 and
CD28 in myeloma CD8+ T cells before and after therapy
with immunomodulatory drugs and dexamethasone. PD-1
and CTLA-4 remained significantly upregulated in treated
patients whereas we observed a trend for downregulation
of 2B4 and CD160, although this was not significant
(Fig. 4a). Notably, the analysis of treated patients pointed
towards a decline of the senescent CD57+CD28− T cell
population (Fig. 4b). Certainly, more data are needed to
confirm these findings.
We also analyzed the percentage of CD3+ T cells
which was lower in treated patients compared to
chemo-naive patients. In detail, the percentages of
CD4+ as well as CD8+ T cells were lower in chemo-
naive patients compared to the treated ones. The CD4
+/CD8+ ratio in treated myeloma patients was also
lower, although results did not reach statistical signifi-
cance (p = 0.06) (Additional file 1: Figure S1). The dis-
tribution of T cell subsets was not significantly altered
except for the decrease of Temra cells in treated patients
(p < 0.05; Additional file 2: Figure S2a). Additionally, we
analyzed T cell subset distribution in untreated patient
samples in correlation to the International Staging System
(ISS). Although sample numbers were low, we identified
changes in the T cell subsets (Tem and Temra) rather
early in disease development in stage I, which were con-
sistent also in higher stages (Additional file 2: Figure S2b).
To complete our studies, we also tested inhibitory
markers’ expression on CD4+ T cells from PB and BM
and also CD8+ T cells from PB of treated myeloma
patients. We found no significant differential expression
between naive and treated CD4+ T cells except for
CD57, which was also downregulated on PB CD8+ T
cells (Additional file 3: Figure S3a–c).
The CD8+CD57+CD28− phenotype may represent cyto-
toxic T cells in myeloma which are terminally differentiated,
Fig. 3 Accumulation of highly activated but senescent CD8+ T cells in the BM of myeloma patients. The expression of CD28 and CD57 was assessed
on CD8+ T cells from patients with multiple myeloma and healthy, age-matched controls. Percentages of a CD8+CD28− T cells or b CD8+CD57+ T
cells in healthy (n = 12) and myeloma samples (n = 12). c Percentages of CD8+CD57+CD28− T cells compared to CD8+CD57+CD28+ T cells (n = 10).
d Concomitant expression of CD57 and PD-1 on CD8+ T cells of the BM of healthy and diseased (n = 6–8). Median with IQR is shown. Significance
levels *p < 0.05; **p < 0.01; ***p < 0.001; n.s. not significant
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i.e., senescent. It is thought that these cells lose their
ability to proliferate under in vitro stimulation [36, 37].
Therefore, we stimulated T cells from healthy donors,
chemo-naive myeloma patients, and treated patients
and measured proliferation and CD57 expression. As
expected, healthy T cells showed a higher proliferation
rate undergoing up to three cell divisions. During pro-
liferation, they lost CD57 expression compared to
chemo-naive myeloma T cells (Fig. 5a–c). However,
proliferation rate, although rather low in myeloma sam-
ples, was about the same in chemo-naïve versus treated
myeloma samples and CD8+ T cells retained compar-
able expression of CD57 (Fig. 5b, c).
Additionally, we observed enhanced overall survival
in chemo-naive patients with high percentage of CD8
+CD28–CD57+ T cells in the bone marrow (prelimin-
ary observations, not shown). These data go along
with observations from Suen et al. [3], but certainly
more patients’ data are needed before drawing definite
conclusions.
Discussion
In this study, we investigated the nature of the T cell de-
fects in multiple myeloma in more detail and compared
our findings to healthy, age-matched donor samples. Such
a thorough study of BM and PB samples from myeloma
patients and healthy individuals has, to our knowledge,
not been performed so far. Our investigation of systemic
and local changes of the expression of checkpoint inhibi-
tor molecules PD-1, CTLA-4, CD160, and 2B4 revealed
significant upregulation of all tested markers especially in
the bone marrow, suggesting that the immunosuppressive
tumor microenvironment fuels immune escape in mul-
tiple myeloma.
Expression and ligation of immune-checkpoint mole-
cules downregulate T cell responses and thereby main-
tain self-tolerance. The use of monoclonal antibodies
(i.e., anti-PD-1) to disrupt receptor-ligand interactions
has already shown remarkable results in the therapy of
several solid tumors [38–40] and is currently a fast pro-
gressing field also in hematological cancers including
Fig. 4 Differential expression of T cell markers in BM of newly diagnosed and refractory myeloma patients. a Percentage of cell surface expression
of exhaustion markers PD1, CTLA-4, CD160, 2B4 was quantified on CD8+ effector T cells from patients with newly diagnosed myeloma (MM naive)
and treated myeloma (MM Tx) compared to healthy donors. b Similar, expression of senescent markers CD57 and CD28 was investigated by flow
cytometry. (Healthy n = 7–12; myeloma newly diagnosed n = 7–11; treated myeloma n = 5–6; median with IQR is shown). Significance levels
*p < 0.05; **p < 0.01; n.s. not significant
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myeloma. A major obstacle is the profoundly suppressive
tumor microenvironment which limits actions of im-
mune cells against cancer [41]. Coupled with the finding
that myeloma cells express PD-L1 which can even be
further upregulated by stroma cell contact, the PD-1
pathway has been shown to contribute to the aggressive-
ness of this disease in a subset of patients [14]. Although
in vitro results strongly support PD-1 inhibition as
novel, effective therapy [16], these drugs failed to induce
major responses in myeloma in vivo so far, as compared
to other B cell malignancies [13]. Here, the tumor
microenvironment emerges as important additional tar-
get and ongoing studies which combine PD-1 inhibitors
with immunomodulatory agents (i.e. lenalidomide and
pomalidomide) appear to be more successful. Lenalido-
mide has been shown to induce immuno-activating
changes in the myeloma microenvironment [15, 42] and
to downregulate PD-L1 expression [14]. However, since
PD-L1 expression per se varies strongly in myeloma
[43], other checkpoint inhibitors might become equally
important targets. Studies in the 5T33 murine myeloma
model already showed the efficacy of lenalidomide in
combination with blockade of other immune check-
points (e.g. CTLA-4, LAG-3, TIM-3, and combinations
thereof [44]). Our analyses show that CTLA-4, 2B4, and
CD160 expression remains high even after IMiD-
containing therapies and thus could constitute additional
novel targets. CTLA-4 competes with the immunosti-
mulatory receptor CD28 for the binding of CD80/CD86
proteins. Tumor engagement of the CTLA-4 pathway
may therefore dampen the immune response in the
microenvironment resulting in an inappropriate T cell
costimulation [45]. In fact, ipilimumab, an antagonistic
antibody of CTLA-4, was the first immune-checkpoint
inhibitor studied in lymphoid malignancies with promis-
ing results [46]. However, investigations in multiple mye-
loma are still pending. CD160, one of the five ligands of
herpes virus entrance mediator (HVEM) has the poten-
tial to shift immune response towards exhaustion, and
its expression has been shown to be independent of PD-
1 [26]. Moreover, CD160 blockade has not been investi-
gated in myeloma so far. CD28 downregulation and 2B4
upregulation in the presence of CTLA-4 has been shown
in a virus-specific T cell model [47]. We here see a
Fig. 5 Proliferation of T cells in myeloma BM expressing CD57. Proliferation was determined by measuring dilution of CFSE using flow cytometry.
Representative plots are shown for CD8+ T cells of (a) a healthy person, b a naive, and (c) a treated myeloma patient. The graphs display the results of
independent experiments performed on samples from a four healthy persons, b seven chemo-naive, and c three treated patients (who were off IMiD-
containing therapy for at least 6 months), showing the percentage of CD8+ T cells within each cell division. On the x-axis, the number of cell divisions
according to CFSE dilution is indicated (G0 undivided; G1-3 1–3 cell divisions; significance levels *p < 0.05; **p < 0.001)
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similar situation in myeloma bone marrow, i.e., a high
proportion of CD8+ T cells which lost CD28 expression
and concomitantly gained CTLA-4 expression and up-
regulated 2B4. These regulations could be the result of
chronic stimulation leading to enhanced T cell exhaus-
tion. The CMV status of the patients might play a role
here, however, recent papers showed defects in T cell
function irrespective of CMV serostatus [48, 49].
Additionally, to our checkpoint molecule analysis, we
detected an altered T cell subset distribution at the
tumor site, leading to a significant increase of the ef-
fector T cell population at the expense of the memory T
cell population. These CD8+ BM T cells would generally
favor anti-cancer immune responses. However, these
cells also displayed upregulation of checkpoint mole-
cules, reduced cytokine production, reduced ability to
degranulate in response to T cell stimulation, and re-
duced proliferative capacity. Thus, without further acti-
vations, these T cells are most likely ineffective in tumor
immune surveillance. The loss of CD28 expression is a
sign of T cell aging in healthy individuals [30], and we
found it further enhanced in myeloma patients. In
addition, we observed that myeloma CD8+CD28− T cells
concomitantly expressed CD57, pointing to a high accu-
mulation of a late differentiated, senescent T cell popula-
tion in the BM. CD8+CD28–CD57+ T cells from
peripheral blood have been shown to play an active pro-
tumor role via suppressing proliferation of responder T
cells [34], and removal of these cells in vitro restored T
cell proliferative capacity [50, 51]. Moreover, CD8
+CD28–CD57+ T lymphocyte clones in the PB of mye-
loma patients have been associated with progressive and
advanced stage disease [52]. In our analyses, we found
that the percentage of CD57+ T cells in the bone mar-
row of treated patients was reduced suggesting a window
of opportunity for effective immune modulatory treat-
ments. However, sample size needs to be extended to be
able to draw solid conclusions about the potential role of
CD8+CD28–CD57+ T cells in myeloma. Clearly, due to
the severe impairment of T cell function, reactivation of T
cells has to be built on several columns. An additional
promising approach demonstrated that exogenous IL-7
added to T cells co-cultured with tumor cells inhibited
loss of CD28, a feature of replicative senescence, and
allowed normal proliferative capacity and IL-2 production
[53]. IL-7 can also induce telomerase activity [54]. Inter-
estingly, an ongoing phase I clinical trial using the non-
glycosylated form of human IL-7 shows promise, in that it
seems to cause the expansion of naive and memory CD4
and CD8 T cell populations (NTC00062049). This may be
important for myeloma patients as especially memory T
cells are reduced at the tumor site. Together with IL-15,
which is a critical factor for development, proliferation
and activation of natural killer cells and CD8+ memory T
cells, it may effectively contribute to fight the tumor. In
preclinical studies, this cytokine exhibited potent antitu-
mor activities against established tumors in animal
models, showing that CD8+ T cells play a pivotal role in
the anti-myeloma effect of IL-15 agonists [55, 56].
Conclusions
In this study, we show that the percentages of CD8+ ef-
fector T cells especially at the tumor site, i.e., the bone
marrow, of myeloma patients are increased but cells are
functionally severely impaired and display several fea-
tures of exhaustion and senescence. Whereas expression
of checkpoint inhibitory molecules is retained during the
course of treatment, senescent T cell-marker CD57 ap-
pears to be downregulated. These data clearly show that
several avenues for the reactivation of the immune re-
sponse in multiple myeloma will finally be needed to de-
velop novel successful therapies.
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